Share
Download
Cite
+ Favorites
Share
Download
Cite
+ Favorites
RESEARCH
Why Bill Gates is “Most Excited” About The Promise of Monoclonal antibodies for COVID-19: Evidence Deep Dive .
OrthoEvidence Journal (OE Journal) - OE Original
OE Journal. 2020;8(14):3Monoclonal antibodies have emerged as one of the most anticipated therapeutic options for COVID-19, with dozens of trials now underway across the globe. Most studies focus on agents like tocilizumab and other IL-6 or GM-CSF blockers aimed at blunting the cytokine-driven inflammation seen in severe disease. Evidence to date comes almost entirely from observational studies, which suggest a possible reduction in mortality—about 60% relative improvement—but with low certainty due to bias and inconsistency. Safety signals have been mixed but generally manageable, with no clear pattern of treatment-related harm. With more than 80 trials in progress, including several large RCTs, stronger evidence is on the way, but for now confidence in benefit remains limited and conclusions should be cautious.
Already have an account? Log in
Part of an association? Click here, you may already have full access!
Unlock the Full original article
You have access to 4 more FREE articles this month.
Click below to unlock and view this original article
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
Are you affiliated with one of our partner associations?
Click here to gain complimentary access as part your association member benefits!
0 of 4 monthly FREE articles unlocked
